TY - JOUR
T1 - Shortened and intensified MJMA
T2 - An effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs
AU - Gobbi, P. G.
AU - Valentino, F.
AU - Lambelet, P.
AU - Perfetti, V.
AU - Bergamaschi, G.
AU - Girino, M.
AU - Corazza, G. R.
PY - 2009
Y1 - 2009
N2 - There is great interest in chemotherapies for relapsed or refractory lymphomas that are both directly effective against the lymphoma and able to mobilize PBSCs for rescue after high-dose chemotherapy (HDC). Twenty-eight patients with relapsed or refractory lymphomas were treated with a shortened, intensified MJMA regimen (mitoxantrone 10 mg/m2 i.v. day 1, carboplatin 200 mg/m2 i.v. days 1-2, methylprednisolone 500 mg/m2 i.v. days 1-3, cytarabine 2000 mg/m2 i.v. day 3) for six cycles every 21 days. A median of five cycles/patient was administered. Nineteen patients had complete responses, seven partial responses and two no responses. The only remarkable toxicity was hematological. In 18 patients who were candidates for HDC, a mean of 10.45 × 106 CD34/kg of patients' body weight was collected (range: 3.70-24.88 × 106/kg). Eleven patients underwent transplantation, which converted two of four partial responses into complete responses. The median follow-up was 49 months. Survival parameters were not related to relapsed/refractory status or to the time from the last chemotherapy, but were related only weakly to the number of prior chemotherapies. Outpatient MJMA is a feasible and very effective salvage chemotherapy per se. The complete response rate is high and it is a powerful PBSC mobilizer.
AB - There is great interest in chemotherapies for relapsed or refractory lymphomas that are both directly effective against the lymphoma and able to mobilize PBSCs for rescue after high-dose chemotherapy (HDC). Twenty-eight patients with relapsed or refractory lymphomas were treated with a shortened, intensified MJMA regimen (mitoxantrone 10 mg/m2 i.v. day 1, carboplatin 200 mg/m2 i.v. days 1-2, methylprednisolone 500 mg/m2 i.v. days 1-3, cytarabine 2000 mg/m2 i.v. day 3) for six cycles every 21 days. A median of five cycles/patient was administered. Nineteen patients had complete responses, seven partial responses and two no responses. The only remarkable toxicity was hematological. In 18 patients who were candidates for HDC, a mean of 10.45 × 106 CD34/kg of patients' body weight was collected (range: 3.70-24.88 × 106/kg). Eleven patients underwent transplantation, which converted two of four partial responses into complete responses. The median follow-up was 49 months. Survival parameters were not related to relapsed/refractory status or to the time from the last chemotherapy, but were related only weakly to the number of prior chemotherapies. Outpatient MJMA is a feasible and very effective salvage chemotherapy per se. The complete response rate is high and it is a powerful PBSC mobilizer.
UR - http://www.scopus.com/inward/record.url?scp=67651097580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651097580&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.421
DO - 10.1038/bmt.2008.421
M3 - Article
C2 - 19139733
AN - SCOPUS:67651097580
VL - 44
SP - 19
EP - 25
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 1
ER -